344 related articles for article (PubMed ID: 15823826)
1. Effect of steroid add-back therapy on the proliferative activity of uterine leiomyoma cells under gonadotropin-releasing hormone agonist therapy.
Mizutani T; Sugihara A; Honma H; Komura H; Nakamuro K; Terada N
Gynecol Endocrinol; 2005 Feb; 20(2):80-3. PubMed ID: 15823826
[TBL] [Abstract][Full Text] [Related]
2. Regulation of dosage of conjugated equine estrogen is useful for add-back therapy.
Hoshimoto K; Hayashi M; Ohkura T
J Med; 2000; 31(3-4):167-75. PubMed ID: 11280448
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of severe menstrual migraine headaches with gonadotropin-releasing hormone agonist and "add-back" therapy.
Murray SC; Muse KN
Fertil Steril; 1997 Feb; 67(2):390-3. PubMed ID: 9022620
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonist use before hysterectomy.
Stovall TG; Summit RL; Washburn SA; Ling FW
Am J Obstet Gynecol; 1994 Jun; 170(6):1744-8; discussion 1748-51. PubMed ID: 8203435
[TBL] [Abstract][Full Text] [Related]
6. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (leuprolide acetate).
Mizutani T; Sugihara A; Nakamuro K; Terada N
J Clin Endocrinol Metab; 1998 Apr; 83(4):1253-5. PubMed ID: 9543151
[TBL] [Abstract][Full Text] [Related]
7. [Clinical use of leuprolide acetate depot in a group of gynecologic patients in the preoperative period].
Russo P; Ciolli P; Atlante M; Carico E; Mancini R; Russo R; Vecchione A
Minerva Ginecol; 1998 Nov; 50(11):499-502. PubMed ID: 9882992
[TBL] [Abstract][Full Text] [Related]
8. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
9. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
10. Effects of four different regimens of hormone replacement therapy on hemostatic parameters: a prospective randomized study.
Taner MZ; Ozpolat E; Taskiran C; Onan MA; Gursel T; Karabulut E; Gursoy R; Himmetoglu O
Maturitas; 2006 Feb; 53(3):267-73. PubMed ID: 15978753
[TBL] [Abstract][Full Text] [Related]
11. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of uterine leiomyoma with depot leuprorelin acetate (Enantone-Gyn monthly depot). Effect on leiomyoma volume and operability. German Leuprorelin Study Group].
Stolz W; Pfützenreuter N
Zentralbl Gynakol; 1997; 119(10):468-75. PubMed ID: 9432825
[TBL] [Abstract][Full Text] [Related]
13. Morphologic patterns of human endometrial epithelium in women with uterine myomata treated with leuprorelin acetate.
Palmara V; Triolo O; Benedetto V; Lo Re C; Sturlese E; Retto G; Santoro G
Gynecol Obstet Invest; 2010; 69(2):131-5. PubMed ID: 19996602
[TBL] [Abstract][Full Text] [Related]
14. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
[TBL] [Abstract][Full Text] [Related]
16. Potential cost savings using GnRH agonists as preoperative therapy for uterine leiomyomas.
Saltiel E
Formulary; 1995 Sep; 30(9):532-4, 542. PubMed ID: 10161243
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy.
Khurana KK; Singh SB; Tatum AH; Schulz V; Badawy SZ
J Reprod Med; 1999 Jun; 44(6):487-92. PubMed ID: 10394541
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis.
Irahara M; Uemura H; Yasui T; Kinoshita H; Yamada M; Tezuka M; Kiyokawa M; Kamada M; Aono T
Gynecol Obstet Invest; 2001; 52(4):217-22. PubMed ID: 11729332
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
